Zhaoke Ophthalmology (HKSE:06622) Cash-to-Debt : 6.14 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zhaoke Ophthalmology's cash to debt ratio for the quarter that ended in Dec. 2023 was 6.14.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Zhaoke Ophthalmology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Zhaoke Ophthalmology's Cash-to-Debt or its related term are showing as below:

HKSE:06622' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.14 Med: 13.08 Max: 57.7
Current: 6.14

During the past 5 years, Zhaoke Ophthalmology's highest Cash to Debt Ratio was 57.70. The lowest was 6.14. And the median was 13.08.

HKSE:06622's Cash-to-Debt is ranked worse than
50.29% of 1527 companies
in the Biotechnology industry
Industry Median: 6.24 vs HKSE:06622: 6.14

Zhaoke Ophthalmology Cash-to-Debt Historical Data

The historical data trend for Zhaoke Ophthalmology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zhaoke Ophthalmology Cash-to-Debt Chart

Zhaoke Ophthalmology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

7.75

23.22

57.70

13.08

6.14

Zhaoke Ophthalmology Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial				57.70	29.71	13.08	8.56	6.14

Competitive Comparison of Zhaoke Ophthalmology's Cash-to-Debt

For the Biotechnology subindustry, Zhaoke Ophthalmology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhaoke Ophthalmology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zhaoke Ophthalmology's Cash-to-Debt falls into.

Zhaoke Ophthalmology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zhaoke Ophthalmology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1598.692	/	(236.433	+	23.914)
	=	6.14

Zhaoke Ophthalmology's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1598.692	/	(236.433	+	23.914)
	=	6.14

Zhaoke Ophthalmology (HKSE:06622) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zhaoke Ophthalmology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhaoke Ophthalmology (HKSE:06622) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN

Website

https://www.zkoph.com

Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.

Executives

Mak Siu Hang Viola	2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd	2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd	2101 Beneficial owner
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Fidelity China Special Situations Plc	2101 Beneficial owner
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Vms Holdings Limited	2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited	2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p.	2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p.	2201 Interest of corporation controlled by you

Zhaoke Ophthalmology (HKSE:06622) Headlines

No Headlines